Loading organizations...
Key people at Biovance Capital.
Biovance Capital operates as a specialized venture capital firm, investing in disruptive, early-stage biopharma companies across Europe. It provides strategic capital for seed and Series A rounds, supporting the development of transformative therapies across diverse modalities and therapeutic areas. The firm actively collaborates with portfolio companies to bring novel medical treatments to patients.
Established in 2023, Biovance Capital was founded by General Partner João Incio, MD, PhD, and Managing Partner Ricardo Perdigão Henriques, PhD. Their insight stemmed from the clear need for a dedicated biotech fund to propel promising European biomedical research onto the global stage, fostering life science innovation.
The firm primarily serves early-stage biopharma companies led by visionary scientists and entrepreneurs. Biovance Capital’s mission is to empower these pioneers with resources to transform lives and redefine medical possibilities. It envisions a future where strategic investment and collaborative support deliver critical new treatments to patients.
Key people at Biovance Capital.
Biovance Capital has 1 tracked investment across 1 company. The latest tracked deal is $636.0M Seed Extension in Laigo Bio in March 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 23, 2026 | Laigo Bio | $636.0M Seed Extension | Biovance Capital, Kurma Partners | Angelini Ventures, ARGOBIO, Cancer Research Horizons, Curie Capital, Eurazeo, Oncode Oncology Bridge Fund, ROM Utrecht Region |
